MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 09/07/22
MaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
MaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 RevenueGlobeNewsWire • 04/12/22
MaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/23/22
MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022GlobeNewsWire • 02/24/22
MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes ProgramsGlobeNewsWire • 02/01/22
MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue ResultsGlobeNewsWire • 01/24/22
MaxCyte, Inc. (MXCT) CEO Douglas Doerfler Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/13/21
MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy ProgramsGlobeNewsWire • 10/28/21